The researchers report that, overall, those who had taken ARBs had a significantly increased likelihood of new cancer diagnosis compared with patients in comparison groups (7.2% as opposed to 6%).
Among the solid-organ cancers examined, only the risk of lung cancer was significantly increased in patients taking ARBs compared with the comparison groups (0.9% as opposed to 0.7%).